Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $3.60 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 132.4% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 15,210 shares of the medical research company's stock after buying an additional 8,665 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in IQVIA were worth $3,604,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. 1832 Asset Management L.P. boosted its position in shares of IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock worth $96,487,000 after buying an additional 376,595 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of IQVIA in the 2nd quarter worth approximately $70,610,000. Impax Asset Management Group plc lifted its position in IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock worth $344,998,000 after purchasing an additional 264,555 shares during the period. Canada Pension Plan Investment Board lifted its stake in IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock valued at $719,634,000 after purchasing an additional 211,653 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its position in shares of IQVIA by 285.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company's stock valued at $56,783,000 after acquiring an additional 198,808 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company's stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company's stock.

IQVIA Price Performance

IQVIA stock traded down $0.53 during trading hours on Wednesday, hitting $215.81. 1,067,804 shares of the stock were exchanged, compared to its average volume of 1,072,028. The stock has a market capitalization of $39.34 billion, a P/E ratio of 28.10, a P/E/G ratio of 2.09 and a beta of 1.49. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The business's 50-day moving average is $236.50 and its two-hundred day moving average is $230.16. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Truist Financial dropped their price target on shares of IQVIA from $300.00 to $286.00 and set a "buy" rating on the stock in a research note on Monday, October 14th. Morgan Stanley lifted their target price on shares of IQVIA from $270.00 to $280.00 and gave the company an "overweight" rating in a research note on Tuesday, July 23rd. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $288.00 to $279.00 and set an "overweight" rating for the company in a research note on Wednesday, October 23rd. StockNews.com raised IQVIA from a "hold" rating to a "buy" rating in a research report on Wednesday. Finally, Barclays lowered their price objective on IQVIA from $275.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, October 15th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $267.27.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.